Study of Breast Cancer Re-irradiation After Second Lumpectomy
Using Intensity Modulated Radiation Therapy IMRT
For ER HER2-negative Patients Aged 40 and Older
Led by Youssef Zeidan · Updated on 2025-11-13
114
Participants Needed
2
Research Sites
260 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and possible harms of reirradiation treatment for breast cancer patients who have already received radiation before surgery. This study focuses on women diagnosed with estrogen receptor-positive and HER2-negative breast cancer who have had a second ipsilateral lumpectomy. The goal is to learn about both the beneficial and adverse effects of this reirradiation approach.
Participants will receive intensity modulated radiation therapy IMRT, delivered as 40 Gy total dose in 15 consecutive weekday sessions targeting the partial breast. Prior radiation treatments including brachytherapy, external beam MV photons, protons, or intraoperative radiation are allowed within dose limits. The study requires a minimum interval of 18 months since the last breast radiotherapy.
During the study, researchers will monitor treatment-related adverse events for one year and assess long-term outcomes such as local recurrence-free survival, overall survival, distant metastasis-free survival, mastectomy-free survival, and patient-rated cosmetic changes over five years. Participants will undergo regular evaluations and follow-up to track these outcomes, with the total participation duration spanning multiple years.
CONDITIONS
Brief Title
Breast Re-irradiation After Second Ipsilateral Lumpectomy
Research Team
Y
Youssef Zeidan, M.D., Ph.D.
M
MCI Multisite Research Program
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
IMRT Partial Breast Re-irradiation
Endocrine Therapy + Surveillance
What it is
This is partial breast re-irradiation delivered via intensity modulated radiation therapy (IMRT), given as 40 Gy in 15 daily fractions to the partial breast, following a second lumpectomy for recurrence in the same breast.
Endocrine therapy (such as tamoxifen or aromatase inhibitor) plus close follow-up is the accepted non-reirradiation standard after a second breast-conserving surgery for an ipsilateral recurrence in estrogen receptor-positive, HER2-negative disease.
Role in trial
This is the only treatment evaluated in the trial, for eligible patients undergoing a second breast-conserving surgery after prior radiotherapy.
Represents current-care management for otherwise similar patients not receiving repeat irradiation after a second lumpectomy.
Primary use or intent
To improve local control and allow further breast conservation in patients with in-breast recurrence after previous radiotherapy and first breast-conserving surgery.
To reduce risk of subsequent recurrence and address hormone-sensitive tumor biology following a second lumpectomy when re-irradiation is not performed.
How it is given or performed
IMRT is delivered to the partial breast, up to a total dose of 40 Gy in 15 consecutive daily sessions after surgery.
Endocrine therapy is administered as a daily oral medication; clinical follow-up involves regular physical exams and imaging as per standard protocols.
Evidence status
Recent studies including prospective trials demonstrate feasibility and acceptable toxicity for partial breast re-irradiation after second lumpectomy, but long-term outcome data remain limited.
Long-term experience supports the use of endocrine therapy plus surveillance as the standard non-reirradiation approach, but the risk of further local recurrence is higher compared with radiotherapy.
Important risks
Potential side effects include skin toxicity, breast induration, fibrosis, and cosmetic changes, as well as rare risk of late tissue damage. Early reports show acceptable toxicity, but long-term risks require further study.
Risks of endocrine therapy include hot flashes, arthralgia, bone density loss, and rare thromboembolic events. Surveillance alone carries no direct treatment risk but does not reduce recurrence probability compared to radiotherapy.
Important limitations
Single-arm trial design without direct randomization limits the ability to compare outcomes directly to standard care. Long-term follow-up is ongoing for late toxicity, and the approach requires specialized technology and expertise.
May be less effective for local control compared to radiotherapy; carries risk of additional recurrence, and does not allow for further breast conservation if re-recurrence occurs.
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 40Years +
FEMALE
Eligibility Criteria
You may qualify if you...
Diagnosed with estrogen receptor-positive, HER2-negative breast cancer
Age 40 years or older
Signed informed consent form
Willing to comply with all study procedures and available for the study duration
Oncotype score less than 26 if postmenopausal, less than 16 if premenopausal, or Low/Ultra-Low index
At least 18 months since last breast radiotherapy session
Prior radiation therapy (brachytherapy, external beam MV photons, protons, or intraoperative radiation) allowed within total dose limit of 68 Gy (EQD2)
Ipsilateral recurrence that is unifocal, less than 3 cm, with negative margins, node-negative, and either carcinoma in situ or invasive
Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less
Planning target volume to whole breast ratio less than 1/2
Life expectancy greater than 12 months
Agreement to use highly effective contraception during screening, treatment, and for one year after treatment if able to become pregnant
You will not qualify if you...
BRCA1/2 mutation or any other breast cancer receptor subtypes besides ER+HER2-
Individuals assigned male at birth with breast cancer
Pregnancy or breastfeeding
Skin involvement by cancer
Presence of distant metastasis
Initial high-risk triple negative or HER-2 enriched breast cancer
Other malignancies except skin cancer
Connective tissue disorders such as scleroderma or lupus
Any other condition that may increase risk as judged by the investigator
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Treatment
Duration - 3 weeks
Participants receive intensity modulated radiation therapy (IMRT), consisting of 40 Gy total delivered in 15 consecutive weekday sessions to the partial breast.
15 weekday visits (in-person)
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Studying Key Non-coding RNAs and Their Interaction With Chromatin Remodeling in Breast Cancer Patients
Phase III Study of Oral Zotiraciclib for Recurrent Malignant Gliomas with IDH1 or IDH2 Mutations
Study of 18F-FAPI-04 PETCT and PETMR Scans for Detecting and Monitoring Various Cancers
Comparing 18F-FDG and 68Ga-FAPI-46 PET Scans in Women With ER-positive Breast Cancer
18F-grazy-02 PETCT Imaging to Monitor Immunotherapy Responses in Adults with Lung Cancer or Melanoma
Evaluating 18F-T2 PETCT Imaging for Detecting Tumors with High CAIX Levels in Adults
Observational Study Comparing 3D and 2D Echocardiography for Early Heart Damage Detection in Patients Receiving Anthracyclines and HER2-Targeted Cancer Therapies
Study Comparing 3D-Printed Biodegradable Breast Implants, Traditional Breast-Conserving Surgery, and Silicone Implant Reconstruction for Breast Cancer Patients
Phase II Trial of 4FMFES-PET Combined with FDG-PET for Diagnosis and Management of Advanced Estrogen Receptor-Positive Breast Cancer
Ultrahypofractionated 5-Session Whole Breast Radiotherapy with Boost versus Standard 15-Session Radiotherapy for Breast Cancer Patients with Unfavorable Characteristics
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
NRG Oncology-Radiation Therapy Oncology Group Study 1014: 1-Year Toxicity Report From a Phase 2 Study of Repeat Breast-Preserving Surgery and 3-Dimensional Conformal Partial-Breast Reirradiation for In-Breast Recurrence.
Douglas W Arthur, Kathryn A Winter, Henry M Kuerer...
Effectiveness of Breast-Conserving Surgery and 3-Dimensional Conformal Partial Breast Reirradiation for Recurrence of Breast Cancer in the Ipsilateral Breast: The NRG Oncology/RTOG 1014 Phase 2 Clinical Trial.
Douglas W Arthur, Kathryn A Winter, Henry M Kuerer...
Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy.
Ivo A Olivotto, Timothy J Whelan, Sameer Parpia...